Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Minerals

cse:lxx

POPULAR ARTICLES

Lexaria's Robust Patent Portfolio Continues to Grow

Lexaria's Robust Patent Portfolio Continues to Grow

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Lexaria Announces New R&D Plans for 2026

Lexaria Announces New R&D Plans for 2026

LATEST ARTICLES

Lexaria Announces Positive Final Results from Human Pilot Study #5

Lexaria Announces Positive Final Results from Human Pilot Study #5

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Latest News

Blue Jay Gold Corp. Announces Engagement of Oak Hill Financial Inc. for Investor Relations and Retention of Haywood Securities for Market Making Services

Nine Mile Metals Commences Trading on the OTCID Market, Expanding Access for U.S. Investors

America's Antimony Gap Is Washington's Problem -- and NevGold Is Racing to Help Close It

QIMC Highlights Technical Advisory Role on First Atlas Matane Natural Hydrogen Project Following Quebec Parliamentary Committee Appearance

Small Cap Growth Virtual Investor Presentations Now Available for On-Demand Viewing

Outlook Reports world

Precious Metals
- Gold
- Silver
Battery Metals
Energy
- Uranium
- Oil and Gas

Base Metals
Critical Metals
- Rare Earths
Industrial Metals
Agriculture

- Cleantech
- Emerging Tech

- Biotech
- Cannabis

- Psychedelics
- Pharmaceuticals

Featured Stocks

Jameson Resources

Jameson Resources (JAL:AU)

JAL:AU

Skyharbour Resources

Skyharbour Resources (SYH:CC)

SYH:CC

Ni-Co Energy

Ni-Co Energy (None)

Freegold Ventures

Freegold Ventures (FVL:CC)

FVL:CC

West High Yield

West High Yield (WHY:CC)

WHY:CC

Quebec Innovative Materials

QIMC:CC

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES